Trade with Eva: Analytics in action >>

Wednesday, November 1, 2017

-=Juno Therapeutics (JUNO) reported earnings on Wed 1 Nov 2017 (a/h)

Juno Therapeutics beats by $0.07, beats on revs
  • Reports Q3 (Sep) loss of $0.73 per share, $0.07 better than the Capital IQ Consensus of ($0.80); revenues rose 115.4% year/year to $44.8 mln vs the $18.12 mln Capital IQ Consensus.
  • Juno expects to be in the lower half of 2017 cash burn guidance, which is cash used in operating activities and capital expenditures, excluding cash inflows or outflows from upfront payments related to business development activities, of between $270 million and $300 million.
  • Cash, cash equivalents, and marketable securities as of September 30, 2017 were $1.06 billion compared to $801.8 million as of June 30, 2017, and $922.3 million as of December 31, 2016.
Clinical Update:
  • Presentations at ASH will include data from the ongoing Phase I TRANSCEND study in patients with relapsed or refractory (r/r) aggressive B-cell NHL who were treated with fludarabine/cyclophosphamide lymphodepletion and JCAR017.
  • New data will be available at multiple presentations, including an oral presentation on Monday, December 11 that will include information on safety and responses.
  • Ongoing enrollment for the pivotal cohort of the TRANSCEND trial at DL2 with BLA filing expected to be completed in the second half of 2018 and with approval as early as 2018. 

No comments:

Post a Comment